An observational study recently published in Cancer highlights a notable correlation between glucose-6-phosphate dehydrogenase (G6PD) deficiency and improved clinical outcomes among patients with ...

Many years ago, my patient, a woman in her fifties with chronic myeloid leukemia (CML), got her routine, yearly lab work returned showing a white blood cell count that was 10 times higher than normal.

An author shares his own story about the "pay me now or pay me later" relationship between cancer chemotherapy and heart disease. (Washington Post) Three pending cases before the U.S. Supreme Court ...

Onureg (azacitidine) is a prescription drug used to treat acute myeloid leukemia (AML) in certain cases. The drug comes as an oral tablet. It’s usually taken once daily for days 1–14 of each 28-day ...

Aurobindo’s Eugia Pharma Specialities subsidiary has received the Food and Drug Administration’s permission for azacitidine for injection, 100 mg single-dose vial, which is the generic of ...

Results from the phase 3 AGILE study presented at SOHO 2022 show that ivosidenib plus azacitidine prolong event-free and overall survival with good responses vs placebo in patients with IDH1-mutated ...

Tibsovo plus Vidaza led to survival benefit for patients with IDH1-mutant acute myeloid leukemia, according to findings from the AGILE clinical trial. Findings from the phase 3 AGILE trial showed ...

Approved three years ago as a solo agent for certain patients with IDH1-mutated acute myeloid leukemia, Servier’s Tibsovo has now scored a wider indication as the company works to expand its use. In ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved azacitidine for treatment of pediatric patients with newly diagnosed juvenile myelomonocytic ...

Gilead Sciences, Inc. GILD recently announced that the FDA has lifted the partial clinical hold placed on studies evaluating its investigational agent magrolimab in combination with Vidaza. Magrolimab ...

Eying growth in oncology, Astellas has suffered an R&D setback for acute myeloid leukemia drug Xospata (gilteritinib). The med flunked a combo trial with Bristol Myers Squibb's Vidaza, but Astellas is ...